Back
PROCEPT BioRobotics investors face September 22, 2026 lead plaintiff deadline in class action

PROCEPT BioRobotics investors face September 22, 2026 lead plaintiff deadline in class action

Northern District of California suit alleges PROCEPT misled investors from February 28, 2024 to February 25, 2026 about demand for Aquablation handpieces and the impact of a bulk-order discount program.

Fact Check
Three independent securities-law-firm notices (Robbins Geller, Kaplan Fox, SueWallSt/Levi & Korsinsky) each confirm a class action against Cogent Communications with a September 21, 2026 lead plaintiff deadline and a February 29, 2024–May 1, 2026 class period. The Robbins Geller notice identifies the underlying case as filed in the U.S. District Court for the District of Columbia (Washington), matching the claim's 'Washington suit' descriptor, and enumerates exactly the alleged misconduct categories cited in the claim: optical wavelength backlog quality, demand, financial targets, dividend sustainability, and CEO stock-pledging risk. No conflicting evidence was found.
    Reference: 123
Summary

Purchasers of PROCEPT BioRobotics Corporation common stock between February 28, 2024 and February 25, 2026 have until September 22, 2026 to seek appointment as lead plaintiff in a securities class action pending in the U.S. District Court for the Northern District of California. The case, Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation, No. 26-cv-07691, alleges the company misrepresented demand for its Aquablation therapy system handpieces by using an undisclosed discount program to encourage customers to place bulk orders beyond actual demand, artificially inflating reported U.S. handpiece unit sales and creating overstocking risks. The complaint says PROCEPT later disclosed with its 2025 and first-quarter 2026 financial results that handpiece sales had materially exceeded procedures in every quarter since the first fiscal quarter of 2023 despite earlier reassurances to the contrary, after which the stock fell more than 18%.

Terms & Concepts
  • lead plaintiff: The investor appointed by the court to represent the proposed class and help direct the litigation.
  • Aquablation therapy system: A PROCEPT device used to treat benign prostatic hyperplasia, or enlarged prostate.
  • benign prostatic hyperplasia: A medical condition, also known as enlarged prostate, that can affect urinary function.